Directors Report of Park Medi World Ltd.

The Board of Directors of Park Medi World Limited (“Company”) have immense pleasure in presenting the 15^th Board’s Report on
the business and operations of the Company, together with the Audited Financial Statements and the Auditors report of the Company
for the financial year (‘FY’) ended on March 31,2026.

Financial Highlights

Key highlights of the financial results of the Company prepared as per the Indian Accounting Standards (“Ind AS”) for the financial
year ended March 31, 2026, along with corresponding numbers of the previous financial year ended March 31,2025, are as under:

State of the Company’s affairs

The Group has reported, on consolidated basis, total income of
INR 17,110 million (“mn”) in FY 2025-26 with profit of INR 3,546
mn vis-a-vis income of INR 14,260 mn with profit of INR 2,857
mn in FY 2024-25. During FY 2025-26, there was no change in
the nature of the business of the Company.

Park Group of Hospitals is North India’s 2^nd largest Hospital
Chain, currently operating an extensive network of 16 hospitals
strategically located across North India with a combined
capacity of 3,960 beds. Primarily, each hospital is managed by
a dedicated separate legal entity to ensure efficient operations
and quality service. The map below provides a visual overview
of these operational and upcoming hospital locations, along with
their bed capacity.

Initial Public Offering and Listing

FY 2025-26 turned out to be one of the most important years in
our journey so far. During the year, the Company has successfully
completed its Initial Public Offering (“IPO”) of 5,67,90,123
Equity Shares comprising a fresh issue of 4,75,30,864 Equity
Shares and an offer for sale, by one of the existing Promoters of
92,59,259 Equity Shares at an offer price of INR 162/- per equity
share (including a premium of INR 160/- per share).

The IPO was opened on December 10, 2025 and closed on
December 12, 2025 (both days inclusive). Subsequently, the
Equity Shares of the Company were listed and admitted for
trading on the BSE Limited and the National Stock Exchange of
India Limited with effect from December 17, 2025.

The Monitoring Agency, CRISIL Ratings Limited, submits
its report on a quarterly basis, outlining any deviation(s) or
variation(s), if any, in the utilization of the public issue proceeds.
These reports are reviewed by the Audit Committee in its
meetings and are thereafter submitted to the Stock Exchanges
as per the applicable regulatory requirements. There has been
no deviation in the utilization of the IPO proceeds of the Company
as on the date of this report.

Material Events during the year
Acquisitions

During the FY 2025-26, the Company has made the
following acquisitions:

1. On June 12, 2025, Aggarwal Hospital and Research Services
Private Limited, a wholly-owned subsidiary of the Company,
entered into a share purchase agreement (“SPA”) and
acquired 55% of the paid-up equity share capital of Devina
Derma Private Limited. Subsequently, on August 23, 2025,
the parties entered into an Addendum to said SPA to acquire
whole shareholding of Devina Derma Private Limited.

2. On December 19, 2025, the Company approved the
acquisition of KP Institute of Medical Sciences (KPIMS),
Agra, with a capacity of 360 beds, through the purchase
of 100% of the existing shareholding of K P S Wellness
Private Limited and SVPD Healthcare Private Limited and
successfully completed the said acquisitions on January 30,
2026, and March 20, 2026, respectively.

3. On December 23, 2025, Blue Heavens Health Care Private
Limited, a wholly-owned subsidiary of the Company has
completed the acquisition of Durha Vitrak Private Limited
which owns Febris Multi-speciality Hospital with a capacity of
200 beds. The said acquisition has been completed pursuant
to the approval of resolution plan by the Hon’ble National
Company Law Tribunal, New Delhi, under the corporate
insolvency resolution process in accordance with the
Insolvency and Bankruptcy Code, 2016.

4. On January 5, 2026, the Company has acquired 100% of
the existing shareholding of Mahip Hospitals Private Limited
which operates the Krishna Super-Speciality Hospital in
Bhatinda with a capacity of 250 beds. The Company had
been managing the operations of this hospital since July
2025 through a separate agreement.

Capacity Expansion

On March 10, 2026, R G S Healthcare Limited, a subsidiary
of the Company, approved the expansion of bed capacity of
Grecian Super Speciality Hospital, Mohali by adding 150 beds
to the existing bed capacity of 350 beds.

The upcoming 150-bed super speciality expansion at Mohali
will focus on strengthening advanced clinical capabilities,
with investments directed toward key high-acuity specialties
including Oncology, Neurosciences, Gastro Sciences, and
Robotic Surgeries. The expansion will also introduce robotic
joint replacement capabilities, significantly enhancing the
hospital’s ability to deliver cutting-edge, minimally invasive
treatment options.

Transfer to Reserves

The Company does not propose to transfer any amount to any
reserve and the entire amount of the profit for FY 2025-26 shall
form part of retained earnings.

Dividend

The Board of Directors (“Board”) does not recommend any
dividend on the equity shares of the Company for the financial
year ended March 31, 2026.

The Dividend Distribution Policy, in terms of Regulation 43A of
the Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations, 2015 (“Listing
Regulations”) is available on the Company’s website at
https://www.parkhospital.in/investor-relations/about-
company/policies

Deposit

The Company neither has any outstanding deposits nor it has
accepted any deposits from the public during FY 2025-26.

Transfer of unclaimed dividend to Investor
Education and Protection Fund

Since no dividend was declared during the year, therefore there
has been no amount which was required to be transferred to the
Investor Education and Protection Fund.

Credit Rating

The Company’s commitment to financial discipline and
prudence is evident from the strong credit ratings assigned by

rating agencies. The Company’s long-term banking facilities are
rated as Crisil A /Stable by CRISIL Ratings Limited.

Subsidiaries, Joint Ventures and Associate
Companies and their performance

As on March 31,2026, the Company has 22 subsidiaries including
step-down subsidiaries. There are 7 Material Subsidiaries of the
Company as per the Listing Regulations as on March 31, 2026.

During FY 2025-26, the following Companies become the
Subsidiaries of the Company:

1. Mahip Hospitals Private Limited - wholly owned subsidiary

2. K P S Wellness Private Limited - wholly owned subsidiary

3. SVPD Healthcare Private Limited - wholly owned subsidiary

4. Devina Derma Private Limited - step down subsidiary

5. Durha Vitrak Private Limited - step down subsidiary

As on March 31, 2026, the Company has no holding, joint
venture or associate company.

In terms of the requirements of Section 129(3) of the Companies
Act, 2013, as amended from time to time (“Act”), a statement
containing salient features of the financial statements of the
Company’s subsidiaries is provided in note no. 56 of the
consolidated financial statement.

The financial statements of the Company and its subsidiaries
for FY 2025- 26 have been prepared in compliance with the
applicable provisions of the Act and the Listing Regulations as
well as in accordance with the Companies (Indian Accounting
Standards) Rules, 2015. The audited standalone and
consolidated financial statements together with the Independent
Auditor’s Report thereon form part of this Annual Report.

The standalone and consolidated audited financial statements of
the Company are available on the Company’s website athttps://
www.parkhospital.in/investor-relations/financial-information.
The financial statements of the subsidiaries, are available on
the Company’s website at https://www.parkhospital.in/investor-
relations/financial-information/group-companies

Share Capital

The authorised share capital of the Company as on March 31,
2026 is INR 125,00,00,000 (Indian Rupees One Hundred and
Twenty-Five Crores only) divided into 62,50,00,000 (Sixty-Two
Crore and Fifty lakhs) Equity Shares of INR 2 each.

The issued, subscribed and paid-up equity share capital as on
March 31, 2026 is INR 86,38,61,728 (Indian Rupees Eighty-
Six Crore Thirty-Eight Lakh Sixty-One Thousand and Seven
Hundred Twenty- Eight only) consisting of 43,19,30,864 equity
shares of face value of INR 2 each.

During the year, the issue, subscribed and paid-up equity share
capital of the Company were increased pursuant to the IPO of
the Company as briefed herein.

Auditors and Auditor’s Report
Statutory Auditor

The Company, in its 13^th Annual General meeting (“AGM”)
appointed M/s Agiwal & Associates, Chartered Accountants,
(Firm Registration Number: 000181N) as Statutory Auditors of the
Company for a period of 5 (Five) consecutive years commencing
from the conclusion of 13^th AGM until the conclusion of 18^th AGM
of the Company to be held in the year 2029 for the FY 2028-29.

There were no observations made by the Statutory Auditors
in their report and the explanations given by them are
self-explanatory.

The Auditor’s Report on the standalone and consolidated
financial statements of the Company for FY 2025-26 forms part
of this Annual Report.

Internal Auditor

NKSC & Co., Chartered Accountants, was appointed as the
Internal Auditor of the Company for the financial year ended
March 31, 2026 and the report given by the Internal Auditor has
been reviewed by the Audit Committee from time to time.

On the recommendation of the Audit Committee, the Board at its
meeting held on May 15, 2026 had approved the appointment
of NKSC & Co., Chartered Accountants, as the Internal Auditor
of the Company for the financial year ending March 31, 2027.

Secretarial Auditor

Pursuant to the extant provisions of Section 204 of the Act, SBR
& Co. LLP, Practicing Company Secretaries, were appointed as
Secretarial Auditor of the Company for FY 2025-26.

Further, as per Regulation 24A of the Listing Regulations, the
material unlisted subsidiaries of the Company as on March 31,
2026 viz. Aggarwal Hospital and Research Services Private
Limited, Blue Heavens Health Care Private Limited, Park Medicity
India Private Limited, Narsingh Hospital & Heart Institute Private
Limited, Park Medicenters and Institutions Private Limited, R G S
Healthcare Limited and Umkal Healthcare Private Limited have
also undertaken a secretarial audit for the FY 2025-26.

The Secretarial Audit Reports of the Company and its
material subsidiaries in ‘Form MR-3’ for the FY 2025-26
have been provided herein as Annexure-I of this report. The
Secretarial Audit reports are unqualified and does not contain
any observation.

Pursuant to Regulation 24A of the Listing Regulations, the Board
on the recommendation of the Audit Committee in its meeting
held on May 15, 2026, has appointed SBR & Co. LLP, Company
Secretaries in Practice, (LLPIN: AAO-9057), as the Secretarial
Auditors of the Company for a period of five consecutive
financial years from 2025-26 to 2029-30. The said appointment
is subject to shareholders’ approval at the ensuing 15^th AGM
of the Company.

SBR & Co. LLP, have confirmed that they are not disqualified to
be appointed as a Secretarial Auditors and are eligible to hold
office as Secretarial Auditors of the Company.

Cost Auditors

Pursuant to the provisions of Section 148 of the Act read with
the Companies (Cost Records and Audit) Rules, 2014 and the
rules made thereunder, Bahuguna & Co., Cost Accountants, was
appointed as Cost Auditor of the Company for the FY 2025-26.
Cost Auditors will submit their report for FY 2025-26 within the
timeframe prescribed under the Act.

The Board on the recommendation of the Audit Committee at
its meeting held on May 15, 2026, appointed Sachin Gupta &
Co. as the Cost auditor for FY 2026-27 subject to ratification of
remuneration payable to said Cost Auditor by the shareholders
in ensuing AGM.

Fraud Reporting

During the year under review, the Statutory Auditor and
Secretarial Auditor of the Company have not reported any
instances of frauds committed in the Company by its Officers or
Employees, to the Audit Committee, as required under Section
143 (12) of the Act.

Meeting of Board of Directors

The Board met 15 (fifteen) times during the FY 2025-26. The
intervening gap between the two Board Meetings did not exceed
120 days, as prescribed under the Act. The details of board
meetings and the attendance of the Directors are provided
in the Corporate Governance Report, which forms part of
this Annual Report.

Committees of the Board

The Committees of the Board play a significant role in
strengthening the Company’s governance framework by
providing focused oversight and effective supervision over
specific functional areas. These committees are constituted
in accordance with the requirements of the Act and
Listing Regulations.

The minutes of the meetings of all Committees are placed
before the Board for its noting and review. The meetings of the
Committees are generally convened prior to the meetings of
the Board, wherever required, and the respective Chairpersons
of the Committees apprise the Board of the key deliberations,
recommendations, and decisions taken at such meetings.

The committees submit their recommendations to the Board
for approval, and during the year, all the recommendations by
the committees were approved. When needed, committees may
also invite special guests to their meetings.

As on March 31, 2026, the Board has six Committees as follows:

1. Audit Committee

2. Nomination and Remuneration Committee

3. Stakeholders Remuneration Committee

4. Corporate Social Responsibility (“CSR”) Committee

5. Risk Management Committee

6. IPO Committee

Details relating to the composition of the Committees, their
terms of reference, number of meetings held, attendance of
members at such meetings, and other requisite information are
provided in the Corporate Governance Report forming part of
this Annual Report.

Audit Committee

The Audit Committee comprises of three members - Mr. Ravi
Krishan Takkar as Chairman, Dr. Ajit Gupta and Dr. Kamlesh
Kohli as members of the Committee. All the recommendations
made by the Audit Committee were accepted by the Board.

Corporate Social Responsibility

The CSR Committee of the Company is inter alia responsible for
formulating, recommending and monitoring the CSR Policy of
the Company which contains the approach and direction given
by the Board, and includes guiding principles for selection,
implementation and monitoring of activities as well as formulation
of the annual action plan.

The composition of the CSR Committee, and other details
including brief outline of the CSR Policy of the Company, the
amount that the Company was required to spent in terms of the
provisions of the Act, and the amount that was actually spent
during the FY 2025-26 are set out in Annexure-II to this Report
in the format as prescribed under the Companies (Corporate
Social Responsibility Policy) Rules, 2014.

Performance Evaluation

Pursuant to the provisions of the Act and the Listing Regulations,
the Nomination and Remuneration Committee has put in
place a framework for annual evaluation of the performance
of the Board of Directors, Board Committees and individual
directors, including the Independent Directors and Chairperson
of the Company. The Board evaluation was conducted through
questionnaire designed with qualitative parameters and feedback
based on ratings. For the FY 2025-26, the evaluation process was
undertaken in accordance with the abovementioned framework
and applicable law. The Board expressed their satisfaction with
the evaluation process.

Policy on Director’s Appointment and Remuneration

The Board and Nomination and Remuneration Committee
reviewed the performance of the individual directors on the
basis of the criteria such as the contribution of the individual
director to the Board and committee meetings like preparedness
on the issues to be discussed, meaningful and constructive
contribution and inputs in meetings, willingness to devote time
and effort to understand the Company and its business by the
Directors, competency to take the responsibility and having
adequate qualification, experience and knowledge, quality and
value of their contributions at board meetings, effectiveness,
leadership quality of the Chairperson etc. The requisite policies
with respect to the above for Directors and Key Managerial

Personnel are available on the website of the Company athttps://
www.parkhospital.in/investor-relations/about-company/policies.

Employee stock option scheme

Pursuant to Board and Shareholders resolutions dated March
11, 2025, and March 14, 2025, respectively, the Company
has adopted “Park - Employees Stock Option Scheme-2025"
("ESOP Scheme"). The Scheme permits grants of stock options
to employees of the Company and its subsidiaries, not exceeding
1% of the Company’s paid-up capital.

The objectives of the ESOP Scheme are inter alia to attract
and retain talent, incentivize employee performance, align
employee interests with long-term shareholder value, promote
sustained growth, and offer a variable pay structure through
deferred rewards.

The ESOP Scheme is in compliance with SEBI (Share Based
Employee Benefits and Sweat Equity) Regulations, 2021.

No options have been granted under ESOP Scheme.

The Company has obtained certificate(s) from its Secretarial
Auditor in accordance with the SEBI (Share Based Employee
Benefits and Sweat Equity) Regulations, 2021 and the
resolution(s) passed by the members of the Company. The said
certificate will be made available for electronic inspection by the
members during the AGM. The requisite disclosures have been
made on the website of the Company.

Material changes and commitment affecting
the financial position of the Company occurred
between the end of the financial year to which
these financial statements relate and the date of
the report

There has not been any such instance to report except the below.

On April 10, 2026, as per its commitment for healthcare
expansion, the Company inaugurated its state-of-the-art multi¬
super speciality hospital in Panchkula. This facility has been
strategically developed to cater to the burgeoning demand for
tertiary and quaternary healthcare services across the catchment
regions of Haryana, Punjab, Himachal Pradesh, and Chandigarh.
Equipped with specialized treatment capabilities across multiple
clinical disciplines, the hospital is well-positioned to meet the

region''s escalating need for advanced and comprehensive
medical care. By bringing world-class healthcare infrastructure
closer to patients in these regions, the hospital is expected to
significantly reduce patients'' dependence on metro cities for
accessing high-end medical treatment.

Independent Directors’ Meeting

The Independent Directors met once on December 04, 2025,
without the attendance of Non-Independent Directors and
members of the management. The Independent Directors
reviewed the performance of Non-Independent Directors,
the Committees and the Board as a whole along with the
performance of the Chairman of the Company, taking into
account the views of Executive Directors and Non-Executive
Directors and assessed the quality, quantity and timeliness of
flow of information between the management and the Board
that is necessary for the Board to effectively and reasonably
perform their duties.

Directors & Key Managerial Personnel
Board of Directors

As on March 31, 2026, the Company’s Board had Six members
comprising of three Executive Directors, three Non-Executive
and Independent Directors including one Woman Director.

The details of Board and Committee composition, tenure of
directors, meetings and other details are available in the Corporate
Governance Report, which forms part of this Annual Report.

There was no change in the Board of Directors of the Company
during FY 2025-26.

Retirement by Rotation

Pursuant to Section 152 of the Act, Dr. Sanjay Sharma (DIN:
07181328), Whole-time Director, retires by rotation at the ensuing
AGM and being eligible offers himself for re-appointment. The
Board on the recommendation of Nomination and Remuneration
Committee, recommends his re-appointment.

Remuneration to Executive Directors

During FY 2025-26, the Executive Directors of the
Company have received remuneration from the
Company and following Subsidiaries:

Key Managerial Personnel

Pursuant to Section 2(51) and 203 of the Act, following are the
Key Managerial Personnel of the Company as on March 31,2026:

1. Dr. Ajit Gupta, Whole Time Director

2. Dr. Ankit Gupta, Managing Director

3. Dr. Sanjay Sharma, Whole-time Director & Chief
Executive Officer

4. Mr. Rajesh Sharma, Chief Financial Officer

5. Mr. Abhishek Kapoor, Company Secretary &

Compliance Officer

There were no changes in the Key Managerial Personnel of the
Company during FY 2025-26.

Declaration by Independent Directors

The Company has received declaration from the Independent
Directors that they meet the criteria of independence as
provided in section 149(6) of the Act read with Regulation 16(1)
(b) of the Listing Regulations and there has been no change in
the circumstances which may affect their status as Independent
Director of the Company. Since, none of the Independent
Directors has completed their tenure of appointment therefore
no Independent Director has been proposed for reappointment.

Further, they have confirmed that their names are registered in
the databank maintained with the Indian Institute of Corporate
Affairs (“IICA”) in accordance with the provisions of section
150 of the Act.

Based on the disclosures received, the Board is of the opinion
that, all the Independent Directors fulfil the conditions specified
in the Act and Listing Regulations and are independent of
the management.

Director’s Responsibility Statement

Pursuant to Section 134(5) of the Act, the Board of Directors to

the best of their knowledge and based on the information and

explanations received from the Company, confirm that:

a. In the preparation of the annual accounts, the applicable
accounting standards have been followed and there are no
material departures;

b. The Directors have selected such accounting policies
and applied them consistently and made judgments and
estimates that are reasonable and prudent so as to give
a true and fair view of the state of affairs of the Company
at the end of the financial year and of the profit of the
Company for that period;

c. The Directors have taken proper and sufficient care for
the maintenance of adequate accounting records in
accordance with the provisions of the Act for safeguarding
the assets of the Company and for preventing and detecting
fraud and other irregularities;

d. The Directors have prepared the annual accounts on a
going concern basis;

e. The Directors have laid down internal financial controls to
be followed by the company and that such internal financial
controls are adequate and operating effectively; and

f. The Directors have devised proper systems to ensure
compliance with the provisions of all applicable laws and
that such systems are adequate and operating effectively.

Registered Office

There has not been any change in registered office

of the Company.

Details of significant & material orders passed by
the regulators or courts or tribunal impacting the
going concern status and Company''s operations
in future

During FY 2025-26, there has been no such order impacting the
going concern status and Company’s operations in future.

Annual Return

In accordance with Section 92(3) read with Section 134(3)(a) of
the Act and the Companies (Management and Administration)
Rules, 2014, the Annual Return of the Company in Form MGT-7, is
available on the Company’s website athttps://www.parkhospital.
in/investor-relations/shareholders-information/annual-return.

Particulars of Employee and Remuneration

The information required under Section 197(12) of the Act read
with rule 5(1) of the Companies (Appointment and Remuneration
of Managerial Personnel) Rules, 2014, relating to percentage
increase in remuneration and the ratio of remuneration of
each Director and Key Managerial Personnel to the median
of employees’ remuneration are provided in Annexure-III
of this report.

The statement containing particulars of employees, as required
under Section 197(12) of the Act read with rule 5(2) and 5(3) of
the Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014, is provided in a separate annexure
forming part of this report. However, in terms of Section 136
of the Act, the Annual Report is being sent to the shareholders
and others entitled thereto, excluding the said annexure, which
is available for inspection by the shareholders at the Registered
Office of the Company during business hours on working days
of the Company. Any member interested in obtaining a copy of
the same may write to the Company Secretary.

Vigil Mechanism and Whistle Blower Policy

The Company has adopted a Vigil mechanism and whistle blower
policy and has established the necessary vigil mechanism for
the Directors and employees to report concerns about any
unethical behavior, actual or suspected fraud or violation of the
Company’s Code of Conduct as per the requirements of Section
177 of the Act and Regulation 22 of the Listing Regulations.
No person has been denied access to the Chairman of Audit
Committee and the Audit Committee. The said policy is available
on the website of the Company athttps://www.parkhospital.in/
investor-relations/about-company/policies.

Risk Management

The Board has constituted a Risk Management Committee to
identify risks across various areas of operations and to formulate
appropriate risk mitigation strategies and policies. The Risk
Management Committee periodically apprised the Board of
Directors of the risk assessment and mitigation procedures

undertaken. In the opinion of the Committee, no risks were
identified that could materially threaten the existence or
operations of the Company. Details of the Risk Management
Committee are provided in the Corporate Governance Report.

Internal Control Systems and Internal Financial
Control

The Company''s internal control systems are commensurate with
the nature of its business, size and complexity of its operations.
For strengthening the internal control system, the Company has
well established internal audit. The internal audit is carried out
by external independent auditor. Those controls are tested and
certified by Internal Auditors.

Significant audit observations and follow up actions thereon,
if any, are reported to the Board. The Board of Directors
reviews adequacy and effectiveness of the Company''s internal
control environment and monitors the implementation of audit
recommendations. During FY 2025-26, no reportable material
weaknesses in controls were observed.

Particulars of Loans, Guarantees or Investments
made under section 186 of the Companies
Act, 2013

The details of loans, guarantees and investments for FY 2025-26
are disclosed in the notes to the standalone financial statements
of the Company.

Particulars of Contracts or Arrangements made
with related parties

All transactions with the related parties are placed before the
Audit Committee for its prior approval. An omnibus approval from
Audit Committee is obtained for the related party transactions
which are repetitive in nature.

All transactions with related parties entered into during FY 2025¬
26 were at arm’s length basis and in the ordinary course of
business, in accordance with the provisions of the Act and the
rules made thereunder, Listing Regulations and the Company’s
Policy on Related Party Transactions. Accordingly, the prescribed
Form AOC-2 is not applicable to the Company for FY 2025-26
and hence does not form part of this report. Members may refer
to Notes of the Standalone Financial Statement which sets out
Related Parties Disclosures.

Pursuant to the provisions of the Listing Regulations there were
no materially significant Related Party Transactions during
the FY 2025-26. Also, in terms of regulation 23 of the Listing
Regulations, the Company has filed half yearly reports to the
stock exchanges, for the related party transactions.

The Policy on Related Party Transactions is available on the
Company’s website at:https://www.parkhospital.in/investor-
relations/about-company/policies.

Disclosures under Sexual Harassment of Women
at Workplace (Prevention, Prohibition& Redressal)
Act, 2013

The Company is in compliance with provisions relating to the
constitution of Internal Complaints Committee under the Sexual
Harassment of Women at Workplace (Prevention, Prohibition
and Redressal) Act, 2013.

During FY 2025-26, the status of complaints received under
Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013 is provided below:

Disclosure under the pending proceedings under
the Insolvency and Bankruptcy Code, 2016

No applications or proceedings initiated or pending against the
Company under the Insolvency and Bankruptcy Code, 2016.

Details of difference between amount of the
valuation done at the time of one-time settlement
and the valuation done while taking loan from the
banks or financial institutions

During the FY 2025-26 there was no one time settlement
executed by the Company with any Bank or Financial Institution.

Conservation Of Energy, Technology Absorption,
Foreign Exchange Earnings and Outgo

Conservation of energy and Technology Absorption

The operations of the Company are not energy intensive.
Nevertheless, the Company remains committed to minimizing
the environmental impact of its operations and continues to
undertake initiatives aimed at enhancing sustainability. The
hospitals under Park Group have adopted environmentally
friendly and energy-efficient equipment and in the ordinary
course of business, continue to implement technologies and
equipment that promote improved energy efficiency.

The Group also promotes responsible consumption practices
through regular monitoring of energy usage, preventive
maintenance of medical and non-medical equipment and
adoption of energy-efficient lighting and infrastructure wherever
feasible. Continuous efforts are undertaken to ensure proper
biomedical waste management and adherence to applicable
environmental and healthcare regulations.

The Company is investing regularly in maintenance and
upgradation of equipment used at the hospitals. Park Group
strives to deploy the best practices and best of technology
available in the operations.

Foreign Exchange Earnings And Outgo

During FY 2025-26, there was an outflow of INR 2,93,61,491 in
foreign exchange and there was no income in foreign exchange.

Secretarial standards

Company is in compliances with the secretarial standards
issued by the Institute of Company Secretaries of India (ICSI)
on Meeting of the Board of Directors (SS - 1) and General
Meeting (SS - 2).

Maternity benefit provided by the company under
maternity benefit Act 1961

During FY 2025-26, the extant provisions of the Maternity
Benefit Act, 1961, were applicable to the Company and have
been duly complied with.

All eligible women employees have been extended the statutory
benefits prescribed under the Act, including paid maternity
leave, continuity of salary and service during the leave period,
and post-maternity support such as nursing breaks and flexible
return-to-work options, as applicable. The Company remains
committed to fostering an inclusive and supportive work
environment that upholds the rights and welfare of its women
employees in accordance with applicable laws.

Board Policies

The details of various policies approved and adopted by the
Board as required under the Act and Listing Regulations
are available on the website of the Company athttps://www.
parkhospital.in/investor-relations/about-company/policies.

Corporate Governance Report

The Company is committed to good corporate governance
practices. The Corporate Governance Report, as stipulated
by Listing Regulations, forms part of this Annual Report along
with the required certificate from a Practicing Company
Secretary, regarding compliance of the conditions of Corporate
Governance norms.

In compliance with corporate governance requirements as
per the Listing Regulations, the Company has formulated and
implemented a Code of Conduct for all Board members and
senior management personnel of the Company (“Code of
Conduct”), who have affirmed the compliance thereto.

The Code of Conduct is available on the website of the
Company athttps://www.parkhospital.in/investor-relations/about-
company/policies.

Business Responsibility and Sustainability Report

For the FY 2025-26, the Business Responsibility and
Sustainability Report under the Listing Regulations is not
applicable to the Company.

Management Discussion and Analysis

The Management Discussion and Analysis Report for the FY 2025-26, as stipulated under the Listing Regulations, is presented in a
section forming part of this Annual Report.

Acknowledgement

The Board places on record its deep sense of appreciation for the committed services by all the employees of the Company. The Board
would also like to place on record their appreciation to financial institutions, bankers and business associates, for their assistance,
cooperation and encouragement extended to the Company.

For and on behalf of the Board of Directors
Park Medi World Limited

Dr. Ajit Gupta

Date: May 15, 2026 Chairman & Whole Time Director

Place: Gurugram DIN: 02865369